Lv6
1699 积分 2021-12-14 加入
Zongertinib in Previously Treated HER2 -Mutant Non–Small-Cell Lung Cancer
5天前
已完结
Devouring Atherosclerotic Plaques: The Engineered Nanorobot Rousing Macrophage Efferocytosis by a Two‐Pronged Strategy
16天前
已完结
Real-world study of isavuconazole adverse events based on pharmacovigilance spontaneous reporting systems
20天前
已完结
Blinatumomab and pancreatitis: an analysis of FAERS, EudraVigilance, and a large urban U.S. patient population data
20天前
已完结
Safety Profiles and Pharmacovigilance Considerations for Recently Patented Anticancer Drugs: Advanced Thyroid Cancer
20天前
已完结
Safety of current treatment options for NTRK fusion-positive cancers
24天前
已完结
Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study
24天前
已完结
NTRK Fusions Identified in Pediatric Tumors: The Frequency, Fusion Partners, and Clinical Outcome
24天前
已完结
Long-Term Tumor Stability After First-Line Treatment With Larotrectinib in an Infant With NTRK2 Fusion–Positive High-Grade Glioma
24天前
已完结
Larotrectinib for Newly Diagnosed Infantile Fibrosarcoma and Other Pediatric NTRK Fusion–Positive Solid Tumors (Children's Oncology Group ADVL1823)
24天前
已关闭
皖公网安备34019202002308
